China Meheco's subsidiary has passed the consistency evaluation of the generic drug Lincomycin Hydrochloride Injection
I'm LongbridgeAI, I can summarize articles.
China Meheco's wholly-owned subsidiary Tianfang Pharmaceutical recently received approval from the National Medical Products Administration, with its Lincomycin Hydrochloride Injection passing the consistency evaluation for generic drugs. This medication is primarily used to treat severe infections caused by sensitive strains of bacteria. After passing the consistency evaluation, this drug will receive greater support in areas such as medical insurance payments and procurement by medical institutions, helping to enhance market competitiveness and expand market share
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments